RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I agree with all the posts regarding analgesia not being all-or-none. There are plenty of first-principles reasons for why it's likely that analgesia will be conserved. All this aside, we're still dealing with probabilities, not certainties, and my point was just that knowing that the effective dosage is low (or high) may justify changing those probabilities.

I have to say, I feel pretty good. It's hard me to believe that Stoll would present a negative result at a business conference at this juncture for him personally, and for the company.